GLP-1 Receptor Agonist and SGLT2 Inhibitor Prescribing in People With Type 1 Diabetes.
作者信息
Li Piaopiao, Li Zhiyan, Staton Elizabeth, Umpierrez Guillermo E, Davis Georgia, Shao Hui, Pasquel Francisco J
机构信息
Hubert Department of Global Health, Emory University Rollins School of Public Health, Atlanta, Georgia.
Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville.
出版信息
JAMA. 2024 Nov 19;332(19):1667-1669. doi: 10.1001/jama.2024.18581.
Abstract
摘要
相似文献
1
GLP-1 Receptor Agonist and SGLT2 Inhibitor Prescribing in People With Type 1 Diabetes.1型糖尿病患者中胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂的处方情况
JAMA. 2024 Nov 19;332(19):1667-1669. doi: 10.1001/jama.2024.18581.
2
Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes.在全国2型糖尿病患者群体中，GLP-1受体激动剂和SGLT2抑制剂使用者的治疗中断情况。
Diabetologia. 2025 May 2. doi: 10.1007/s00125-025-06439-x.
3
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists and Sodium/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure and Mortality in Patients With Type 2 Diabetes and CKD.胰高血糖素样肽-1受体激动剂与钠/葡萄糖协同转运蛋白2抑制剂在预防2型糖尿病合并慢性肾脏病患者慢性肾衰竭及死亡方面的比较疗效
Am J Kidney Dis. 2025 Apr 29. doi: 10.1053/j.ajkd.2025.03.016.
4
Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.用于慢性肾病和糖尿病患者的胰高血糖素样肽1（GLP-1）受体激动剂。
Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.
5
Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a network meta-analysis of population-based cohort studies.在 2 型糖尿病患者中使用二肽基肽酶-4 抑制剂、胰高血糖素样肽-1 受体激动剂或钠-葡萄糖共转运蛋白-2 抑制剂与骨折风险的关系：基于人群队列研究的网络荟萃分析。
Front Endocrinol (Lausanne). 2024 Oct 11;15:1410883. doi: 10.3389/fendo.2024.1410883. eCollection 2024.
6
Variation in uptake of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor analogues in adults with type 2 diabetes at high cardiovascular risk.心血管高危2型糖尿病成年患者中钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体类似物的使用差异
Eur J Clin Pharmacol. 2025 Jun 30. doi: 10.1007/s00228-025-03870-2.
7
SGLT2 inhibitors reduce epicardial adipose tissue more than GLP-1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta-analysis.在2型糖尿病和/或肥胖患者中，钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂比胰高血糖素样肽-1（GLP-1）激动剂或运动干预更能减少心外膜脂肪组织：一项系统评价和网状Meta分析。
Diabetes Obes Metab. 2025 Mar;27(3):1096-1112. doi: 10.1111/dom.16107. Epub 2024 Dec 6.
8
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.用于治疗糖尿病和慢性肾脏病患者的胰岛素及降糖药物。
Cochrane Database Syst Rev. 2018 Sep 24;9(9):CD011798. doi: 10.1002/14651858.CD011798.pub2.
9
Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂、胰高血糖素样肽 1 激动剂和二肽基肽酶 4 抑制剂与 2 型糖尿病患者肾脏结局的关系：系统评价和网络荟萃分析。
PLoS One. 2022 Apr 14;17(4):e0267025. doi: 10.1371/journal.pone.0267025. eCollection 2022.
10
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂治疗 2 型糖尿病：随机对照试验的系统评价和网络荟萃分析。
BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573.
引用本文的文献
1
[Phenotypic Classification of Diabetes: A Personalized Approach for Pharmaceutical Practice].[糖尿病的表型分类：药物治疗实践的个性化方法]
Farm Comunitarios. 2025 Jul 1;17(3):76-89. doi: 10.33620/FC.2173-9218.(2025).23. eCollection 2025 Jul 15.
2
Insulin Resistance in Type 1 Diabetes: Concepts and Implications for Therapy.1型糖尿病中的胰岛素抵抗：概念及治疗意义
J Diabetes. 2025 Jul;17(7):e70126. doi: 10.1111/1753-0407.70126.
3
Registration and Real-Life Studies on Automated Insulin Delivery Systems.自动胰岛素输注系统的注册及真实世界研究
J Diabetes Sci Technol. 2025 Jul;19(4):924-936. doi: 10.1177/19322968251334993. Epub 2025 Jul 1.
4
Early Stages of Automated Insulin Delivery.自动胰岛素输注的早期阶段
J Diabetes Sci Technol. 2025 Jul;19(4):908-923. doi: 10.1177/19322968251335685. Epub 2025 Jul 1.
5
Trends in obesity and glucagon-like peptide-1 receptor agonist prescriptions in type 1 diabetes in the United States.美国1型糖尿病患者肥胖及胰高血糖素样肽-1受体激动剂处方的趋势
Diabetes Obes Metab. 2025 Jun;27(6):2967-2976. doi: 10.1111/dom.16300. Epub 2025 Mar 3.
6
Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults.揭示第二代肠促胰岛素类似物司美格鲁肽和替尔泊肽在1型糖尿病及成人隐匿性自身免疫性糖尿病中的治疗潜力。
J Clin Med. 2025 Feb 15;14(4):1303. doi: 10.3390/jcm14041303.
7
Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?胰高血糖素样肽-1受体激动剂与1型糖尿病：会是一个潜在的游戏规则改变者吗？
Front Endocrinol (Lausanne). 2025 Jan 21;15:1520313. doi: 10.3389/fendo.2024.1520313. eCollection 2024.
8
Diabetes: Recent Advances and Future Perspectives.糖尿病：最新进展与未来展望
Biomedicines. 2024 Dec 18;12(12):2875. doi: 10.3390/biomedicines12122875.
本文引用的文献
1
Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.GLP-1 受体激动剂和 SGLT2 抑制剂在 1 型糖尿病中的临床和安全性结局：一项真实世界研究。
J Clin Endocrinol Metab. 2023 Mar 10;108(4):920-930. doi: 10.1210/clinem/dgac618.
2
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.降糖药物治疗 2 型糖尿病的疗效比较：系统评价和网络荟萃分析。
Ann Intern Med. 2020 Aug 18;173(4):278-286. doi: 10.7326/M20-0864. Epub 2020 Jun 30.
3
Use of Adjuvant Pharmacotherapy in Type 1 Diabetes: International Comparison of 49,996 Individuals in the Prospective Diabetes Follow-up and T1D Exchange Registries.1型糖尿病辅助药物治疗的应用：前瞻性糖尿病随访和T1D交换登记处49996例个体的国际比较。
Diabetes Care. 2017 Oct;40(10):e139-e140. doi: 10.2337/dc17-0403. Epub 2017 Aug 2.
4
Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.利拉鲁肽治疗血糖控制不佳的超重 1 型糖尿病成年患者的疗效和安全性（Lira-1）：一项随机、双盲、安慰剂对照试验。
Lancet Diabetes Endocrinol. 2016 Mar;4(3):221-232. doi: 10.1016/S2213-8587(15)00436-2. Epub 2015 Dec 3.
Zotero 插件